A Moloney murine leukemia virus based retroviral vector was used to transfer the bacterial neomycin resistance gene (neon) into feline hematopoietic cells. We reconstituted four cats that had been lethally irradiated with autologous bone marrow that had been infected with the N2 or SAX retroviral vector. Bone marrow cells from all four cats expressed the neon gene 30 days posttransplant and three of four cats still had the neon gene and a low level of drug resistant colonyforming unit granulocyte-macrophage after more than 200 days. Two of the four cats unexpectedly developed diabetes ENE THERAPY is the insertion of a normal gene into
A Moloney murine leukemia virus based retroviral vector was used to transfer the bacterial neomycin resistance gene (neon) into feline hematopoietic cells. We reconstituted four cats that had been lethally irradiated with autologous bone marrow that had been infected with the N2 or SAX retroviral vector. Bone marrow cells from all four cats expressed the neon gene 30 days posttransplant and three of four cats still had the neon gene and a low level of drug resistant colonyforming unit granulocyte-macrophage after more than 200 days. Two of the four cats unexpectedly developed diabetes ENE THERAPY is the insertion of a normal gene into G an organism to correct a genetic defect. Prospects for human gene therapy have increased with the development of retroviral vectors for efficient gene transfer into cells.' Hematopoietic stem cells are one possible target cell for gene transfer into intact organisms because they are capable of self-renewal and undergo expansion with multiple rounds of replication during hematopoietic differentiation. We and others have shown that exogenous genes are expressed during in vitro culture of hematopoietic progenitor cells from mice,'.'' dog^,'^.'^ cats,16 sheep,I7 monkeys," and human^.'^'" In mice, exogenous genes have been shown to be stably integrated in chromosomal DNA from hematopoietic cells after retroviral infection in vitro and bone marrow tran~plantation.'.~~ The infected hematopoietic cells in the recipients were capable of reconstituting lethally irradiated secondary recipients, indicating that the pluripotent stem cells had been infected?." Expression of the bacterial neomycin resistance gene (neo") promoted by a viral long terminal repeat (LTR) in some expression of the human P-globin gene in mouse erythroleukemia cells and human erythroid cells in ~i t r o , '~-~~ and lineagespecific expression of the human @-globin gene in murine transplant recipients reconstituted with retroviral-transduced stem cellsz has shown that retroviral vectors can be used to transfer and express exogenous genes in hematopoietic progenitor cells.
Long-term expression of retroviral-transduced genes in hematopoietic stem cells from adult animals in species other than mice and the fate of exogenous genes in individual animals of any species has not been reported. The dog and cat are potentially excellent large animal models to test gene therapy because they, like humans, are not inbred species and many genetic disorders similar to human diseases have been well characterized in these As a first step to evaluating gene therapy in animal models, we have shown that a retroviral vector can be used to transfer and express an exogenous gene in hematopoietic cells in vivo.
MATERIALS AND METHODS
Adult cats of both sexes were used in these studies. All animals had been previously vaccinated and dewormed and were disease free for at least 2 months before experimental study. These studies were approved by the instituExperimental animals. Retroviral infection and bone marrow transplantation (BMT). BM was obtained by percutaneous aspiration of long bones using ketaminelylazine sedation. BM mononuclear cells were prepared by ficoll-hypaque gradient sedimentation and infected with the N2 or SAX retroviral ~ector,'~.'~ which contain the bacterial neon gene, using a "supernatant" infection protocol described previously.1s,16 Briefly, BM cells were incubated for 4 to 6 hours with conditioned medium from high titer clones, V-6 or S3A, of the amphotrophic packaging cell line PAW' that had been previously transfected with the N2 or SAX vectors, respectively. Conditioned medium from V-6 or S3A cells routinely has a titer of 3 to 5 x lo6 drug-resistant colony-forming units/mL (CFUlmL) and contains approximately 0.1% helper virus contamination. After infection, cells were washed three times with complete medium (Iscove's modified Dulbecco's medium [IMDM] ) and plated in the colonyforming unit granulocyte-macrophage (CFU-GM) assay (see below) or infused into the donor animals that had received 7.5 Gy (0.125 Gyimin) total body irradiation from a Cobalt 60 source (Picker, Cleveland, OH). Animals were kept in a clean isolated room, treated with antibiotics and fluids as indicated until BM reconstitution was evident based on complete blood counts (CBCs).
The CFU-GM were determined as previously Briefly, 7.5 x 10' nucleated marrow cells were plated in 35"' dishes and CFU-GM were enumerated after 6 to 8 days of culture. The antibiotic G418, when added, was present at a CFU-GM assay.
~ ~ 238 LOTHROPETAL concentration of 2 mg/mL. The total amount present was 4 mg/mL because only about 50% of stock G418 is active. DNA was prepared from BM cells by sodium dodecyl sulfate (SDS)-proteinase K digestion, phenolkhloroform extraction, and ethanol precipitation by standard procedures.)* BM DNA (1 Fg) was specifically amplified for neoR sequences by the polymerase chain reaction (PCR) method39 and Southern blotting. The PCR reaction conditions (30 cycles of 94°C for 2 minutes and 45 seconds, 53°C for 2 minutes, and 72°C for 3 minutes and 30 seconds) were performed as described",% using a Gene-Amp kit (Perkin-Elmer Cetus, Norwalk, CT) and an automated thermal cycler (DNA Thermal Cycler; Perkin-Elmer Cetus, or Twinblock system temperature cycler; Ericomp, San Diego, CA). The oligonucleotide primers (CAAGATGGATTGCACGCAGG, CCCGCT-CAGAAGAACTCGTC) permitted amplification of a 790-bp region of the neoR gene. The Southern blots were probed with an oligonucleotide (CCAGGCTCAAGGCGCGCATGC) that hybridizes to a region of the neo" gene between the PCR primers or with the entire neo" gene (pNeo; Pharmacia, Piscataway, NJ). The oligonucleotide primers (ACCTGGAGAGTCACCAACC, TACTITGGAGAGGTCGTAGC) permitted amplification of a 375-bp region of the env gene using reaction conditions 94°C for 2 minutes, 56°C for 2 minutes, and 72°C for 2 minutes for 30 cycles. The oligonucleotide probe (ATGTGGGCTTCCAGTAAGC) used
DNA anabsysis.
to probe the Southern blot hybridizes to a region of the env gene between the primers.
NPT activity was determined according to the method of Reiss et aI4' as previously described." CFU-GM colonies resistant to G418 were recovered from methyl cellulose cultures, washed extensively, and stored as a "dry" pellet at -70°C until analysis.
Neomycin phosphotransferase (NPT) assay.
RESULTS
Four cats that had been lethally irradiated (7.5 Gy) were reconstituted with autologous BM that had been infected with the N2 retroviral vector (n = 3) or the derivative vector, SAX (n = l), to investigate the usefulness of the cat as a model for evaluating gene therapy protocols and to follow the long-term stability and expression of exogenous genes in individual animals. We chose to use the N2 vectors in these studies because the neoR gene in this vector was expressed in murine transplant recipients as well as feline and canine hematopoietic stem cells in v i t r~.~~~~~~~~~ BM reconstitution was evident in all four cats by 20 days posttransplantation based on evaluation of the polymor- The CFU-GM were determined as described. The data are presented as total CFU-GM of five individual culture dishes (7.5 x lo5 cells/dish). Control marrow (uninfected marrow from the same animal [day 0 only] or marrow from an uninfected cat) was assayed in parallel to check for "background" G418-resistant CFU-GM. The MOI is the ratio of viral particles, as estimated by the titer of drug-resistant 3T3 CFUs, to BM mononuclear cells.
Retroviral infection and BMT
Abbreviation: ND, not done.
For For personal use only. on November 11, 2017. by guest www.bloodjournal.org From 240 LOTHROPETAL phonuclear leukocyte (PMN) and platelet counts. The PMN and platelet counts had returned to at least 5,000 PMN/pL and 50,000 platelets/kL in the four cats by 18.5 2 5.4 (mean f SD) and 16.0 f 4.7 days, respectively. This finding indicated that retroviral infection, per se, did not preclude BM reconstitution in an autologous transplantation protocol. Although gastrointestinal toxicity and hematologic complications were observed to various degrees in most animals, the severity was not greater than that observed previously from lethal irradiation and autologous BMT alone.
The results of the pretransplant BM infections, cell doses for transplantation, and multiplicity of infection (MOI) for each cat are summarized in Table 1 . The pretransplant infection rate (day 0) was 5.9%, 3.3%, and 0% in the three animals that were evaluated. These results are similar to our previous finding^".'^ on small-scale BM infections and indicated that the "supernatant" infection protocol was adequate for large-scale BM infections required in a large animal retroviral infection/autologous BMT protocol.
DNA was prepared from BM mononuclear cells both before and after retroviral infection to test for the presence of the neoR gene in the transplanted animals. The neoR gene was not detected in BM cells from the transplanted animals by standard Southern hybridization techniques, suggesting that the neoR gene was present in fewer than 5% of the BM cells. However, when DNA from BM samples from three of the same animals was specifically amplified for neoR sequences by PCR and Southern blotting (Fig l) , the neoR gene was detected in two animals 26 days posttransplant (lanes 2 and 7), and one animal 154 days after retroviral infection/BMT (lane 4). The neoR gene was not detected in BM samples before retroviral infection (Fig 1, lanes 1, 3, and 6 ). Sequential evaluation of BM marrow mononuclear cell DNA from two cats showed that the neoR gene was stili detectable after 200 days. The neoR gene was detected in Martina 214 and 609 days following transplantation but not 978 days following transplantation (Fig 2A) . The neoR gene was also detected in Yenkee 26,67,214,609, and 978 days following transplantation (Fig 2B) .
BM obtained from the transplanted animals from approximately 30 days to greater than 300 days posttransplant was tested for expression of the neoR gene with the in vitro CFU assay. Expression of the neoR gene was evident in all four cats 30 days posttransplantation based on the CFU assay ( Table 1 ). The fraction of BM progenitor cells expressing the neoR gene in the autologous BMT recipients was initially similar to that observed previously with in vitro infection experiments with a comparable MOI. Sequential evaluation of BM for G418-resistant CFU showed that the fraction of G418-resistant CFU declined over a period of several months, but the three cats that could be examined still had a low level of drug-resistant CFU-GM after 200 days. NPT activity was detected in one of two cats 26 days posttransplant, confirming that G418 resistance can be associated with enzyme activity (Fig 3) . Enzyme activity was not detected in BM samples from DNA analysis.
CFU-GM analysis.
Martina and Yenkee 96,214, and 248 days or from Andy 94, 223, 348, and 368 days following transplant, even though several samples were positive for the neoR gene by PCR and Southern blotting and had drug-resistant CFU-GM. This finding suggests that the CFU-GM assay and PCR and Southern blotting may be more sensitive than direct enzyme assay for detecting the neoR gene in transplanted animals.
PCR detection of helper virus. The replicative-defective retroviral vectors N2 and SAX were encapsulated using the amphotrophic packaging cell line
The PA12 cell line has a low level of helper virus contamination with clones expressing the N2 g e n~m e . For personal use only. on November 11, 2017. by guest www.bloodjournal.org From genome was detected in BM DNA in two of three cats that were evaluated (Fig 4) . The two animals positive for the env gene had been infected with the N2 vector, while the negative cat had been infected with the S A X vector. The presence of the helper virus genome in the transplanted cats means a localized BM helper virus infection may have contributed to the persistent expression of the neoR gene in two of the transplanted animals. However, the cat infected with the S A X vector had stable expression of the neoR gene for at least 248 days and was negative for the helper virus genome. However, it is possible the cat is still helper virus-positive because the cat was exposed to helper virus at the time of BM infection but the virus cannot be detected.
Application of retroviral vector-mediated gene transfer to treatment of human genetic diseases is not only dependent on demonstrated efficacy in an animal model system but also the relative assurance that this technology will not induce significant disease in treated patients. Two of the four transplanted cats unexpectedly developed diabetes mellitus approximately 90 days posttransplantation. Islet amyloid, the characteristic histologic abnormality seen in pancreases Diabetes mellitus in transplanted cats.
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env+ from spontaneously diabetic cats,"' was not observed on histologic examination of the pancreases from the two transplanted cats. Postmortem examination of both cats was normal except for a p-cell deficiency and islet atrophy (Fig 5) .
DISCUSSION
The results of the current study demonstrate that an exogenous gene can be expressed in feline hematopoietic cells after reconstitution of lethally irradiated donors with retroviral-infected autologous BM. The expression of a foreign gene in cats, albeit in a small number of cells, demonstrates that retroviral vectors can be used for gene transfer in noninbred large animal species and may be useful for gene therapy of humans. The basis for the decrease in the fraction of cells expressing the neoR gene several months posttransplant was not determined in the current study, but several possibilities exist: (1) the pluripotent stem cells were not adequately infected in the current transplantation protocol and committed cell clones could not be detected after several months; (2) infected stem cell destruction and eventual diabetes mellitus. Viruses are thought to be the common environmental factor inducing diabetes in susceptible people:' Similarly, one of the diabetic cats in our study clearly had detectable amphotrophic virus envelope sequences in BM before development of diabetes mellitus (Fig 3) . Although the exact cause of diabetes in the two transplanted cats is not known, the potential for helper virus-induced disease exists. The unexplained diabetes mellitus in two cats that had been previously infected with N2 retroviral-rich supernatant from the PA12 retrovirus packaging cell line, which is contaminated with 4070A amphotrophic helper retrovirus, demonstrates the potential importance of using helper virus-free retroviral vectors for human gene therapy.
The findings of the current study suggest that retroviral LTR transcriptional regulatory sequences are active in feline hematopoietic progenitor cells. Previous studies have shown that LTR sequences were not always transcriptionally active in murine transplant recipients. The variability in expression of retroviral-transduced genes indicates that retroviral vectors may have to be empirically evaluated for transcriptional activity until the DNA sequences and reguFor personal use only. on November 11, 2017 . by guest www.bloodjournal.org From 244 LOTHROPETAL latory factors controlling expression of retroviral-transduced genes in hematopoietic progenitor cells are defined better. Although we have shown that an exogenous gene can be expressed in feline hematopoietic progenitor cells in vivo, improvement of current retroviral vector infection protocols is necessary to achieve stable transfer and expression of exogenous genes in the majority of BM cells. Animal models of human genetic diseases should be extremely useful for designing and evaluating safe gene therapy protocols for treatment of human genetic diseases.
